The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Feasibility and Preliminary Efficacy of Hatha Yoga in Head and Neck Cancer Survivors

Not Applicable

Completed

Conditions: Head Neck Cancer

Interventions: Other: Baseline Study Measures
Behavioral: Yoga Evaluation
Behavioral: Yoga Program
Behavioral: Yoga Practice Plan
Other: Study Assessments

First Posted Date: 2013-09-27

Last Posted Date: 2016-04-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 40

Registration Number: NCT01951664

Locations: 🇺🇸
Vanderbilt University School of Nursing, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Ultra High Field MRI and MRS Techniques in Diagnosing Breast Cancer

Not Applicable

Terminated

Conditions: Breast Cancer

Interventions: Procedure: high field strength magnetic resonance imaging
Procedure: magnetic resonance spectroscopic imaging
Procedure: chemical exchange saturation transfer magnetic resonance imaging
Procedure: diffusion-weighted magnetic resonance imaging
Procedure: dynamic contrast-enhanced magnetic resonance imaging

First Posted Date: 2013-09-10

Last Posted Date: 2016-08-03

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 3

Registration Number: NCT01938651

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Phase 2

Withdrawn

Conditions: Stage IV Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer

Interventions: Drug: pemetrexed disodium
Drug: carboplatin
Drug: cisplatin
Drug: erlotinib hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2013-08-23

Last Posted Date: 2015-07-13

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Registration Number: NCT01928160

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Triple Negative Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer
Triple-negative Breast Cancer
Estrogen Receptor Negative Breast Cancer

Interventions: Drug: cisplatin
Other: laboratory biomarker analysis
Other: pharmacological study
Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI
Drug: GDC -0941

First Posted Date: 2013-08-07

Last Posted Date: 2017-06-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 11

Registration Number: NCT01918306

Locations: 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸
Georgetown University, Washington, D.C., District of Columbia, United States

and more 13 locations

ALL-Active: A Family-Based Lifestyle Program for Pediatric Acute Leukemia Patients

Not Applicable

Completed

Conditions: Childhood Acute Lymphoblastic Leukemia in Remission

Interventions: Dietary Supplement: nutritional intervention
Behavioral: exercise intervention
Other: follow-up care
Behavioral: counseling intervention
Other: quality-of-life assessment
Other: laboratory biomarker analysis
Other: questionnaire administration

First Posted Date: 2013-07-17

Last Posted Date: 2018-05-08

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 33

Registration Number: NCT01901367

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States

A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma

Phase 1

Completed

Conditions: Malignant Glioma

Interventions: Drug: Bevacizumab
Drug: Temozolomide
Dietary Supplement: Vitamin C

First Posted Date: 2013-07-03

Last Posted Date: 2022-03-10

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 14

Registration Number: NCT01891747

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma

Not Applicable

Terminated

Conditions: Paget's Disease
Osteosarcoma
Ewing Sarcoma

Interventions: Other: DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI

First Posted Date: 2013-06-20

Last Posted Date: 2017-05-08

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 6

Registration Number: NCT01882231

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Non-Myeloablative Conditioning and Bone Marrow Transplantation

Not Applicable

Active, not recruiting

Conditions: Hemoglobinopathies
Sickle Cell Disease

Interventions: Drug: Thymoglobulin
Drug: Fludarabine
Drug: Cyclophosphamide (CTX)
Drug: Mesna
Drug: Sirolimus
Drug: Mycophenolate mofetil (MMF)
Procedure: Bone marrow transplantation
Radiation: Total body irradiation

First Posted Date: 2013-05-09

Last Posted Date: 2024-01-10

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 26

Registration Number: NCT01850108

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇫🇷
Saint-Louis Hospital, Paris, France
🇬🇧
St Mary's Hospital, London, United Kingdom

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Phase 1

Active, not recruiting

Conditions: Stage IV Breast Cancer
Estrogen Receptor-positive Breast Cancer
HER2-negative Breast Cancer
Invasive Ductal Breast Carcinoma
Progesterone Receptor-positive Breast Cancer
Recurrent Breast Cancer

Interventions: Drug: PI3K inhibitor BYL719
Drug: letrozole
Other: laboratory biomarker analysis
Other: pharmacological studies

First Posted Date: 2013-02-15

Last Posted Date: 2024-07-23

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 46

Registration Number: NCT01791478

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Massachusetts General Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer

Early Phase 1

Terminated

Conditions: Adenocarcinoma of the Lung
Recurrent Non-small Cell Lung Cancer
Stage IA Non-small Cell Lung Cancer
Stage IIB Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIA Non-small Cell Lung Cancer
Stage IB Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Drug: acetylsalicylic acid
Other: laboratory biomarker analysis

First Posted Date: 2012-10-16

Last Posted Date: 2020-01-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 4

Registration Number: NCT01707823

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy